Immunocore
IMCR
149 hedge funds and large institutions have $1.79B invested in Immunocore in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 38 reducing their positions, and 10 closing their positions.
210% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 10
42% more call options, than puts
Call options by funds: $4.57M | Put options by funds: $3.23M
29% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 38
13% more funds holding
Funds holding: 132 → 149 (+17)
4.41% more ownership
Funds ownership: 97.61% → 102.02% (+4.4%)
0% more capital invested
Capital invested by funds: $1.79B → $1.79B (+$1.07M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$20.7M |
| 2 |
Janus Henderson Group
London,
|
+$16M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$11.4M |
| 4 |
AC
Armistice Capital
New York
|
+$9.67M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$38.9M |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$13M |
| 3 |
Millennium Management
New York
|
-$12.5M |
| 4 |
Citigroup
New York
|
-$7.71M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$5.39M |
IMCR Hedge Fund Activity: Q4 2025 in Review
149 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q4 2025, worth a combined $1.79B — up 0.06% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new IMCR positions and 10 closed out — a net gain of 21 holders — while 49 added to existing stakes and 38 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $20.7M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $38.9M.
- 149 institutional investors held Immunocore (IMCR) as of Q4 2025, up from 132 in Q3 2025.
- Funds reported $1.79B of Immunocore stock for Q4 2025, up 0.06% quarter-over-quarter.
- 31 funds opened new Immunocore positions in Q4 2025 and 10 closed out, a net change of +21 holders.
- The largest Immunocore buyer in Q4 2025 was Vestal Point Capital, an estimated $20.7M added.
- The largest Immunocore seller in Q4 2025 was T. Rowe Price Investment Management, an estimated $38.9M sold.
Based on aggregated 13F filings for Q4 2025.